Meda acquires remaining Xerese rights in North America

Meda acquires remaining Xerese rights in North America

In February 2010, Meda in-licensed exclusive North American rights to
Xerese - a patented product for treatment of cold sores (herpes
labialis). Under that agreement, Meda pays the collaboration partner
Medivir AB mid-teens and minimum royalties on net sales. Today, Meda has
acquired all rights for Xerese in North America and the royalties have
been reduced to zero. The purchase price was 45 MUSD. Under the terms of
the new agreement, Meda will seek to develop new products for which
Medivir will receive mid-single digit royalties on net sales and a
milestone payment of 10 MUSD on approval by the U.S. Food and Drug
Administration.

For further inquiries, please contact:

Anders Larnholt, Vice President Corporate Development & IR ph: 46
709-458 878